Aegis to Present Intravail® Non-Invasive Drug Delivery and ProTek® Peptide/Protein Stabilization Technology at the 2014 BIO International Convention

SAN DIEGO, CA June 2, 2014 — Aegis Therapeutics LLC will present its Intravail® non-invasive drug delivery technology and its ProTek® protein stabilization technology at the 2014 BIO International Convention in San Diego, taking place June 23- 26, 2014.

Aegis Therapeutics is a drug delivery technology company commercializing its patented drug delivery and drug formulation technologies through product-specific licenses. Our Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide drugs that can currently only be administered by injection, via the oral, buccal, and intranasal administration routes, and with high bioavailability.  Our ProTek® excipients stabilize, prevent aggregation, and reduce unwanted immunogenicity of protein and peptide therapeutics while avoiding the oxidative damage and resulting unwanted immunogenicity caused by polysorbate surfactants currently found in most protein injectable drugs.

Reformulation with the Intravail® technology provides improved product performance and extended patent protection to increase market share and extend product lifecycles. Improvements include increased nasal or oral systemic bioavailability, noninvasive delivery of otherwise injectable-only products, rapid onset of drug action, and circumvention of the “first-pass” elimination effect.

Reformulation with ProTek® excipient technology allows creation of “bio-betters” by preventing peptide or protein aggregation while circumventing oxidative damage caused by polysorbate surfactants, which are used in more than 70% of current biotherapeutics.  ProTek® excipients increase manufacturing yields by eliminating membrane and column fouling, reduce shear-stress damage during pumping and filling operations, and extend product shelf life overall.

A brief introductory presentation will be given by Dr. Edward Maggio, Chief Executive Officer, at 4:15 PM on Wednesday June 25, 2014.  Representatives of Aegis will be available for discussions with interested potential licensees throughout the conference. Meetings with Aegis may be scheduled using the BIO online “One-On-One Partnering System” (http://convention.bio.org/partner/) or may be set up directly with Aegis by contacting Ralph Barry at the contact coordinates shown above.

To receive future press releases directly via email click here and enter your email address in the sign-up box at the bottom of the page.

About Aegis Therapeutics

Aegis Therapeutics LLC commercializes its patented drug formulation technologies through product-specific licenses.  Intravail® drug delivery technology enables non-invasive delivery of a broad range of protein, peptide and non-peptide drugs that can currently only be administered by injection, via the oral, buccal, and intranasal administration routes, and with high bioavailability.  Our ProTek® excipients stabilize, prevent aggregation, and reduce unwanted immunogenicity of protein and peptide therapeutics while avoiding oxidative damage caused by polysorbate surfactants.

For more information about Aegis, please visit:  http://www.aegisthera.com.